Here is a complete, structured overview of modern laxatives based on Katzung's Basic and Clinical Pharmacology and Sleisenger & Fordtran's Gastrointestinal and Liver Disease:
Modern Laxatives - Complete Classification
1. Bulk-Forming Laxatives
Mechanism: Indigestible, hydrophilic colloids that absorb water, form a bulky gel, distend the colon, and stimulate peristalsis.
Onset: 12-72 hours
| Drug | Source |
|---|
| Psyllium (Isabgol) | Natural (plant) |
| Methylcellulose | Semisynthetic |
| Polycarbophil | Synthetic |
| Wheat bran / dietary fibre | Natural |
- Safe for long-term use; require adequate fluid intake
- May cause bloating and flatus due to bacterial fermentation
2. Stool Softeners / Surfactant Agents
Mechanism: Allow water and lipids to penetrate fecal material, softening the stool.
| Drug | Route |
|---|
| Docusate sodium | Oral or enema |
| Docusate calcium | Oral |
| Glycerin suppository | Rectal |
| Mineral oil | Oral (lubricant) |
- Mineral oil lubricates and retards water absorption from stool
- Long-term mineral oil use impairs absorption of fat-soluble vitamins (A, D, E, K); aspiration risk
3. Osmotic Laxatives
Mechanism: Non-absorbable compounds that create an osmotic gradient, drawing water into the colon and increasing stool liquidity.
Onset: 1-3 hours (purgative doses); 12-48 hours (laxative doses)
a) Saline Osmotics
| Drug | Notes |
|---|
| Magnesium hydroxide (Milk of Magnesia) | Avoid in renal insufficiency (risk of hypermagnesemia) |
| Magnesium sulfate | Potent; used for bowel prep |
| Magnesium citrate | Bowel prep |
| Sodium phosphate | Bowel prep; caution in renal disease |
b) Non-absorbable Sugars
| Drug | Notes |
|---|
| Lactulose | Metabolized by colonic bacteria; causes flatus and cramps; also used in hepatic encephalopathy |
| Sorbitol | Similar to lactulose; cheaper |
c) Polyethylene Glycol (PEG)
| Drug | Notes |
|---|
| PEG 3350 (Miralax) | 17 g/day for chronic constipation; no cramps or flatus; safe in all patients |
| PEG + electrolytes (GoLYTELY, NuLYTELY) | Isotonic solution for full colonic cleansing before colonoscopy; 2-4 L |
4. Stimulant Laxatives (Cathartics)
Mechanism: Stimulate the enteric nervous system and colonic electrolyte/fluid secretion, promoting propulsive contractions.
Onset: 6-12 hours (oral); 30-60 minutes (rectal)
a) Anthraquinone Derivatives
| Drug | Notes |
|---|
| Senna (Cassia angustifolia) | Most widely used; 6-12 hours oral action |
| Cascara sagrada | Milder; long-term use causes melanosis coli |
| Aloe | Potent; generally avoided |
b) Diphenylmethane Derivatives
| Drug | Notes |
|---|
| Bisacodyl (Dulcolax) | Oral or suppository; 6-10 hours oral, 30-60 min rectal; used in bowel prep |
| Sodium picosulfate | Prodrug, activated by colonic bacteria |
- Chronic use causes "melanosis coli" (brown pigmentation of colon)
- Long-term use is generally considered safe in most patients per recent evidence
5. Chloride Secretion Activators (Intestinal Secretagogues)
These are newer, prescription agents for chronic idiopathic constipation (CIC) and IBS-C.
a) Chloride Channel (CIC-2) Activator
| Drug | Dose | Notes |
|---|
| Lubiprostone (Amitiza) | 24 mcg twice daily (CIC); 8 mcg twice daily (IBS-C) | Stimulates type-2 Cl⁻ channel; >50% get bowel movement within 24h; may cause nausea |
b) Guanylate Cyclase-C (GC-C) Agonists
| Drug | Dose | Notes |
|---|
| Linaclotide (Linzess) | 145 mcg/day (CIC); 290 mcg/day (IBS-C) | Minimally absorbed peptide; activates GC-C → ↑cGMP → CFTR activation → Cl⁻ and HCO₃⁻ secretion; also reduces visceral pain |
| Plecanatide (Trulance) | 3 mg/day | Uroguanylin analogue; similar mechanism to linaclotide |
6. Opioid Receptor Antagonists (for Opioid-Induced Constipation)
Mechanism: Peripherally acting μ-opioid receptor antagonists - block enteric opioid receptors without crossing the blood-brain barrier (no reversal of analgesia).
| Drug | Route | Dose | Notes |
|---|
| Naloxegol (Movantik) | Oral | 12.5-25 mg once daily | CYP3A4 substrate |
| Naldemedine (Symproic) | Oral | 0.2 mg once daily | CYP3A4 substrate |
| Methylnaltrexone (Relistor) | SC or oral | 0.15 mg/kg SC or 450 mg oral | Used in palliative care |
| Alvimopan (Entereg) | Oral | 12 mg | Short-term only; postoperative ileus in hospitalized patients; cardiovascular risk limits use |
7. Serotonin 5-HT4 Receptor Agonists (Prokinetics)
Mechanism: Activate 5-HT4 receptors → ↑cAMP → release of acetylcholine → high-amplitude propulsive contractions (HAPC) throughout the GI tract.
| Drug | Dose | Notes |
|---|
| Prucalopride (Motegrity) | 2 mg once daily | Approved for chronic constipation; reduces colonic transit time by ~12 hours; no cardiovascular risk (unlike older agents) |
Note: Older 5-HT4 agonists cisapride and tegaserod were withdrawn from markets due to cardiac adverse effects (hERG K⁺ channel blockade).
Summary Table
| Class | Onset | Examples | Best Used For |
|---|
| Bulk-forming | 12-72 h | Psyllium, methylcellulose | Mild/chronic constipation |
| Softeners/Lubricants | 12-72 h | Docusate, mineral oil | Prevent straining |
| Osmotic (saline) | 1-6 h | Mg(OH)₂, sodium phosphate | Acute, bowel prep |
| Osmotic (sugar/PEG) | 24-48 h | Lactulose, PEG 3350 | Chronic constipation |
| Stimulant | 6-12 h oral | Bisacodyl, senna | Acute; opioid-induced |
| Secretagogues | 24 h | Lubiprostone, linaclotide, plecanatide | CIC, IBS-C |
| Opioid antagonists | Hours | Naloxegol, methylnaltrexone | Opioid-induced constipation |
| 5-HT4 agonists | 24-48 h | Prucalopride | Chronic constipation |
Per the
2024 ASCRS guidelines,
osmotic laxatives are first-line pharmacotherapy for chronic constipation, with stimulant laxatives (bisacodyl) as rescue or second-line therapy. Newer secretagogues (linaclotide, plecanatide, lubiprostone) and prucalopride are reserved for patients who fail first-line agents.
Sources: - Katzung's Basic and Clinical Pharmacology, 16th Ed. - Sleisenger & Fordtran's GI and Liver Disease - Yamada's Textbook of Gastroenterology, 7th Ed.